康美药业
(600518)
| 流通市值：185.22亿 | | | 总市值：185.31亿 |
| 流通股本：138.22亿 | | | 总股本：138.29亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 3,527,428,979.25 | 2,290,489,817.26 | 1,079,786,637.44 | 5,252,215,058.26 |
| 营业总成本 | 3,566,250,010.2 | 2,341,857,641.18 | 1,098,903,388.14 | 5,360,814,274.25 |
| 其他经营收益 | | | | |
| 营业利润 | 99,778,316.87 | 35,410,359.68 | -13,331,236.09 | 35,011,099.83 |
| 利润总额 | 101,099,399.84 | 40,999,009.3 | -14,007,250.42 | 43,115,914.49 |
| 净利润 | 95,510,700.71 | 37,367,319.7 | -15,980,697.84 | 12,429,169.97 |
| 每股收益 | | | | |
| 其他综合收益 | -32,437.12 | -25,018.7 | -15,805.99 | -80,909.46 |
| 综合收益总额 | 95,478,263.59 | 37,342,301 | -15,996,503.83 | 12,348,260.51 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 6,618,990,584.2 | 6,660,033,438.49 | 6,803,467,737.62 | 6,651,428,280.98 |
| 非流动资产: | | | | |
| 非流动资产合计 | 6,293,703,277.33 | 6,407,943,420.97 | 6,503,818,479.48 | 6,568,317,706.52 |
| 资产总计 | 12,912,693,861.53 | 13,067,976,859.46 | 13,307,286,217.1 | 13,219,745,987.5 |
| 流动负债: | | | | |
| 流动负债合计 | 4,890,142,631.96 | 5,097,140,814.55 | 5,377,618,653.14 | 5,265,890,988.78 |
| 非流动负债: | | | | |
| 非流动负债合计 | 601,687,608.24 | 608,415,416.86 | 620,163,661.95 | 628,447,463.74 |
| 负债合计 | 5,491,830,240.2 | 5,705,556,231.41 | 5,997,782,315.09 | 5,894,338,452.52 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 7,383,020,385.65 | 7,325,686,836.82 | 7,273,519,463.33 | 7,290,006,280.85 |
| 股东权益合计 | 7,420,863,621.33 | 7,362,420,628.05 | 7,309,503,902.01 | 7,325,407,534.98 |
| 负债和股东权益合计 | 12,912,693,861.53 | 13,067,976,859.46 | 13,307,286,217.1 | 13,219,745,987.5 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 3,988,978,719.33 | 2,584,320,981.13 | 1,117,376,663.23 | 5,583,275,223.81 |
| 经营活动现金流出小计 | 3,891,131,438 | 2,548,268,137.62 | 1,172,132,012.49 | 5,471,928,595.94 |
| 经营活动产生的现金流量净额 | 97,847,281.33 | 36,052,843.51 | -54,755,349.26 | 111,346,627.87 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,842,571.49 | 2,632,998.79 | 2,149,942.5 | 39,788,889.32 |
| 投资活动现金流出小计 | 47,145,615.16 | 29,770,624.32 | 15,701,885.89 | 217,059,298.38 |
| 投资活动产生的现金流量净额 | -44,303,043.67 | -27,137,625.53 | -13,551,943.39 | -177,270,409.06 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 100,480,722.45 | 92,461,627.58 | 42,312,265.95 | 377,320,528.09 |
| 筹资活动现金流出小计 | 26,059,106.76 | 17,116,213.87 | 8,587,100.3 | 88,070,284.94 |
| 筹资活动产生的现金流量净额 | 74,421,615.69 | 75,345,413.71 | 33,725,165.65 | 289,250,243.15 |
| 汇率变动对现金及现金等价物的影响 | -35,951.69 | -28,399.8 | -16,599.73 | -13,988.28 |
| 现金及现金等价物净增加额 | 127,929,901.66 | 84,232,231.89 | -34,598,726.73 | 223,312,473.68 |
| 期末现金及现金等价物余额 | 1,194,222,247.11 | 1,150,524,577.34 | 1,031,693,618.72 | 1,066,292,345.45 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 84,232,231.89 | - | 223,312,473.68 |